Citigroup Inc Oyster Point Pharma, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$7.95 - $11.68 $147,583 - $216,827	18,564 Added 5912.1%	18,878 $210,000
Q3 2022 Nov 10, 2022	SELL	$4.41 - $8.38 $873 - $1,659	-198 Reduced 38.67%	314 $2,000
Q2 2022 Aug 10, 2022	SELL	$3.6 - $11.2 $1,911 - $5,947	-531 Reduced 50.91%	512 $2,000
Q1 2022 May 12, 2022	SELL	$8.58 - $17.65 $753,581 - $1.55 Million	-87,830 Reduced 98.83%	1,043 $12,000
Q4 2021 Feb 10, 2022	BUY	$10.17 - $18.96 $890,922 - $1.66 Million	87,603 Added 6897.87%	88,873 $1.62 Million
Q3 2021 Nov 10, 2021	BUY	$11.67 - $18.07 $14,820 - $22,948	1,270 New	1,270 $15,000

19K

Ticker OYST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,831,500
Description
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.